Ask AI

Translating Evidence Into Practice: Pharmacist-Led Optimization of Adjuvant CDK4/6 Therapy in High-Risk HR+/HER2- Early Breast Cancer

Enhance your understanding of adjuvant CDK4/6 inhibitors currently used to manage high-risk HR-positive/HER2-negative early breast cancer (EBC) to optimally integrate pharmacist-led strategies into patient care through a certified podcast and on-demand webcast, as well as an expert-written ClinicalThought commentary and downloadable slides.

Share

Program Content

Activities

Adjuvant CDK46i Optimization
Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2026

Expires: September 12, 2026

Activities

Optimization of Adjuvant CDK46 Therapy
Translating Evidence Into Practice: Pharmacist-Led Optimization of Adjuvant CDK4/6 Therapy in High-Risk HR+/HER2- Early Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 25, 2026

Activities

CDK4 6 therapy in HR positive HER2 negative BC
Translating Evidence Into Practice: Optimization of CDK4/6 Therapy in HR+/HER2- EBC
Video
Congratulations: You achieved a completion on 04/09/2022

Released: May 12, 2026

Expires: November 11, 2026

Activities

CDK4 6 Patient Counseling in EBC
Navigating Patient Conversations on Adjuvant CDK4/6 Inhibitors in High-Risk HR+/HER2− Early Breast Cancer: Insights for Pharmacists
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 06, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Lilly.

Lilly